About Laurus Labs Limited
Data last updated: 23 December 2025
Laurus Labs Limited is a public limited company based in Anakapalle, Andhra Pradesh, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 19 September 2005, the company has been in operation for over 21 years.
Registered with ROC Vijayawada under CIN U24239AP2005PTC047518. Listed on BSE: 540222 and NSE: LAURUSLABS.
Capital: an authorised share capital of ₹111 Cr and a paid-up capital of ₹107.97 Cr. Formerly known as Aptuit Laurus Limited and Laurus Labs Private Limited. It is led by directors including Venkateswar Reddy Gogireddy and Rajesh Koshy Chandy.
Last AGM: 26 June 2025. Financial statements filed for year ended 31 March 2025. Office: Anakapalle, Andhra Pradesh.
As per the financials filed for FY 2025, the company reported a revenue of ₹5,613.89 Cr, a growth of 11% compared to the previous year.
The company has a workforce of approximately 5,881 employees as per the latest available data.
The company is associated with 2 brands - Laurus Labs, Laurus Bio. As per MCA filings, the company has open charges of ₹2,062.31 Cr and satisfied charges of ₹3,804.21 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lauruslabs.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressLaurus Enclave Plot Office 01 E. Bonangi Village, Parawada (M) Anakapalli District, Anakapalle, Andhra Pradesh, India – 531021
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Laurus Labs Limited
Laurus Labs Limited has undergone 4 name changes throughout its history. The current legal name is Laurus Labs Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Laurus Labs Limited | Current |
| Aptuit Laurus Limited | Previous |
| Laurus Labs Private Limited | Previous |
| Aptuit Laurus Private Limited | Previous |
CIN History of Laurus Labs Limited
Laurus Labs Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239AP2005PLC047518, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239AP2005PLC047518 | Current |
| U24239AP2005PTC047518 | Previous |
| U24239AP2005PLC047518 | Previous |
Associated Brands with Laurus Labs Limited
Laurus Labs Limited operates two associated brands: Laurus Labs and Laurus Bio. These brands represent Laurus Labs Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical and biotechnology company | lauruslabs.com | |
| Precision fermentation services for biopharma and food are provided. | laurus.bio |
Competitors & Alternatives of Laurus Labs Limited
Brands and companies operating in the same space as Laurus Labs Limited include KBI Biopharma, Symbiotec, Aldevron and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
KBI Biopharma
|
Provider of protein formulation, process & cell line development, and cGMP services | Durham, United States, United States | 1996 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Aldevron
|
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | Fargo, United States, United States | 1998 |
Ovagen
|
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services | Mayo, Ireland, Ireland | 2000 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Omnia Biologics
|
Process development and manufacturing services for biologics are provided. | Rockville, United States, United States | 2001 |
Apicore
|
APIs are manufactured and custom synthesis services are provided. | Somerset, United States, United States | 2004 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Kemwell Biopharma
|
Integrated biologics development and manufacturing are provided as a CDMO. | Bengaluru, India, India | 1980 |
Business Activity of Laurus Labs Limited
Laurus Labs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Laurus Labs Limited
Laurus Labs Limited is currently managed by 14 directors, with 28 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Venkateswar Reddy Gogireddy
Also directs:
Sriam Labs Private Limited
|
Nodal Officer | 20 May 2024 | 2 Years 1 Months | Current |
| Rajesh Koshy Chandy | Director | 27 Jul 2016 | 9 Years 11 Months | Current |
| Venkata Ravi Kumar Vantaram | Whole-Time Director | 30 Nov 2006 | 19 Years 7 Months | Current |
|
Aruna Rajendra Bhinge
Also directs:
Laurus Bio Private Limited, Punjab Chemicals And Crop Protection Limited, Mahindra Epc Irrigation Limited and 1 more
|
Director | 07 Jul 2016 | 10 Years 0 Months | Current |
|
Ramesh Subrahmanian
Also directs:
Integris Medtech Limited
|
Director | 25 Jul 2024 | 1 Years 11 Months | Current |
|
Chava Satyanarayana
Also directs:
Laurus Bio Private Limited, Krka Pharma Private Limited, Chemiasoft Private Limited and 1 more
|
Whole-Time Director | 21 Jan 2006 | 20 Years 5 Months | Current |
Financials of Laurus Labs Limited FY 2025 filings available
Laurus Labs Limited reported revenue of ₹5,613.89 Cr (up 11% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Laurus Labs Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Mar 2025 | Others | ₹200 Cr | Open |
| 29 Aug 2024 | Others | ₹258 Cr | Open |
| 16 May 2022 | Sbicap Trustee Company Limited | ₹1,604.31 Cr | Open |
| 06 Dec 2023 | Hdfc Bank Limited | ₹200 Cr | Satisfied |
| 14 Mar 2023 | Axis Bank Limited | ₹200 Cr | Satisfied |
Total charge records: 37 View all charges
Employees and EPFO Compliance at Laurus Labs Limited
View historical data on people associated with Laurus Labs Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Laurus Labs Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Laurus Labs Limited
GSTIN & GST Filing Data of Laurus Labs Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Laurus Labs Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Laurus Labs Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Laurus Labs Limited
MSME Payment Delays by Laurus Labs Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Laurus Labs Limited
Subsidiaries & Group Companies of Laurus Labs Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Laurus Labs Limited with ownership details.
MCA Filings & Documents of Laurus Labs Limited
MCA Filings & Documents of Laurus Labs Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Laurus Labs Limited
Recent News on Laurus Labs Limited
Frequently Asked Questions about Laurus Labs Limited
Laurus Labs Limited is an active public limited company in the pharma sector based in Anakapalle, Andhra Pradesh, India. It was incorporated on 19 September 2005 (21+ years old) and is registered under CIN L24239AP2005PLC047518. Listed on BSE: 540222 and NSE: LAURUSLABS. The company has 5,881 employees.
Laurus Labs Limited reported revenue of ₹5,613.89 Cr for FY 2025 (up 11.00% YoY).
The current directors of Laurus Labs Limited are:
- Venkateswar Reddy Gogireddy
- Rajesh Koshy Chandy
- Chava Satyanarayana
- Venkata Ravi Kumar Vantaram
- Gogireddy Venkateswar Reddy
- Aruna Rajendra Bhinge
- Ramesh Subrahmanian
- Venkata Lakshmana Rao Chunduru
- Soumya Chava
- Ravindranath Kancherla
- Sekar Karnam
- Krishna Chaitanya Chava
- Venkateswar Reddy Gogireddy
- Satyanarayana Chava
The primary industry of Laurus Labs Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Laurus Labs Limited is listed on both BSE (code: 540222) and NSE (symbol: LAURUSLABS).
Laurus Labs Limited can be reached at the registered office: Laurus Enclave Plot Office 01 E. Bonangi Village, Parawada M Anakapalli District, Anakapalle, Andhra Pradesh, India – 531021, or through the website lauruslabs.com.